Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:gup.ub.gu.se/226583" > Treatment of obese ...

1 of 1
Previous record
Next record
To hitlist

Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

Svensson, Johan, 1964 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

Jansson, John-Olov, 1954 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

Ottosson, Malin, 1959 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

Johannsson, Gudmundur, 1960 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

Taskinen, M R (author)

Wiklund, Olov, 1943 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

Bengtsson, Bengt-Åke, 1944 (author): Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine

show less...

(creator_code:org_t)

The Endocrine Society, 1999
1999
English.
In: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 84:6, s. 2028-33

Related links:: https://academic.oup...; show more...; https://gup.ub.gu.se...; https://doi.org/10.1...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Obesity is associated with blunted GH secretion and an unfavorable lipoprotein pattern. The objective of this study was to investigate the effects of treatment with the oral GH secretagogue MK-677 on lipoproteins in otherwise healthy obese males. The study was randomized, double blind, and parallel. Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks. MK-677 treatment did not significantly change serum lipoprotein(a) [Lp(a)] levels. Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end. Serum total cholesterol and low density lipoprotein (LDL) cholesterol (LDL-C) levels were not significantly changed by MK-677 treatment. Serum high density lipoprotein (HDL) cholesterol (HDL-C) was increased at 2 weeks of MK-677 treatment (P < 0.01 vs. placebo), but not at 8 weeks. The LDL-C/HDL-C ratio was reduced after 8 weeks of MK-677 treatment (P < 0.05 vs. placebo). Mean LDL particle diameter was decreased at 2 weeks (P < 0.05 vs. placebo), but was unchanged compared with baseline values at 8 weeks (P = NS vs. placebo). The level of serum triglycerides was increased at 2 (P < 0.05 vs. placebo), but not at 8, weeks. Lipoprotein lipase activity in abdominal and gluteal sc adipose tissue was not affected by active treatment. In conclusion, treatment with the oral GH secretagogue MK-677 affected circulating lipoproteins. The effects on serum apoA-1, apoE, triglycerides, and mean LDL particle diameter were transient. At study end, the LDL-C/HDL-C ratio was decreased. MK-677 treatment did not significantly affect serum Lp(a) concentrations at the present dose and administration protocol.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

Adipose Tissue
drug effects
metabolism
Adult
Anti-Obesity Agents
administration & dosage
therapeutic use
Apolipoproteins A
blood
Cholesterol
LDL
blood
Diet
Double-Blind Method
Human Growth Hormone
blood
secretion
Humans
Indoles
administration & dosage
therapeutic use
Injections
Subcutaneous
Lipoprotein(a)
blood
Lipoproteins
blood
Male
Middle Aged
Obesity
blood
drug therapy
Particle Size
Spiro Compounds
administration & dosage
therapeutic use
Triglycerides
blood

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

The Journal of clinical endocrinology and metabolism (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Svensson, Johan, ...; Jansson, John-Ol ...; Ottosson, Malin, ...; Johannsson, Gudm ...; Taskinen, M R; Wiklund, Olov, 1 ...; show more...; Bengtsson, Bengt ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Endocrinology an ...

Articles in the publication: The Journal of c ...

By the university: University of Gothenburg

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se